Tanaka Yusuke, Kawakami Ayaka, Nanimatsu Ami, Horio Misaki, Matsuoka Jumpei, Wada Takami, Kasaoka Satoshi, Yoshikawa Hiroshi
Laboratory of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hiroshima International University, 5-1-1 Hiro-koshingai, Kure, Hiroshima 737-0112, Japan.
Laboratory of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hiroshima International University, 5-1-1 Hiro-koshingai, Kure, Hiroshima 737-0112, Japan.
Eur J Pharm Sci. 2017 Jan 1;96:464-471. doi: 10.1016/j.ejps.2016.10.023. Epub 2016 Oct 20.
The aim of this study is to evaluate how supersaturation, precipitation, and re-dissolution processes influence the intestinal absorption of cinnarizine (CNZ), a lipophilic weak base, by monitoring its plasma and luminal concentration-time profile, after oral administration as a HCl solution containing fluorescein isothiocyanate dextran (FD-4), a non-absorbable marker. In the in vitro pH shift experiment, the supersaturation stability was significantly lower when the higher-concentration solution of CNZ (pH1.5) was added to the simulated intestinal fluid. However, although the in vivo bioavailability after oral administration of high and low dose as HCl solutions was greatly improved compared to those as neutral suspensions, the difference in the supersaturation stability was not reflected in the improvement of the in vivo bioavailability. Analysis of CNZ and FD-4 concentrations in each segment of the gastrointestinal tract revealed that most of the CNZ precipitated in the duodenum after gastric emptying, and supersaturation was observed only in the duodenum. Thereafter, the precipitate was rapidly re-dissolved and absorbed in the upper and middle small intestine. The rapid re-dissolution may be caused by smaller particles of the precipitate. In this case, it is considered that the key process for the absorption of CNZ was re-dissolution, not supersaturation. Therefore, different supersaturation stabilities in different doses observed in in vitro precipitation experiment was not reflected to in vivo absorption. These findings may be useful to design efficient supersaturable formulations and to validate and improve current prediction methods.
本研究的目的是通过监测口服含有异硫氰酸荧光素葡聚糖(FD-4,一种不可吸收的标记物)的盐酸溶液后西尼地平(CNZ,一种亲脂性弱碱)的血浆和肠腔浓度-时间曲线,评估过饱和、沉淀和再溶解过程如何影响其肠道吸收。在体外pH变化实验中,当将较高浓度的CNZ溶液(pH1.5)加入模拟肠液中时,过饱和稳定性显著降低。然而,尽管与中性混悬液相比,口服高剂量和低剂量盐酸溶液后的体内生物利用度有了很大提高,但过饱和稳定性的差异并未反映在体内生物利用度的提高上。对胃肠道各段中CNZ和FD-4浓度的分析表明,大部分CNZ在胃排空后在十二指肠中沉淀,仅在十二指肠中观察到过饱和现象。此后,沉淀物在小肠上部和中部迅速再溶解并被吸收。快速再溶解可能是由于沉淀物颗粒较小所致。在这种情况下,认为CNZ吸收的关键过程是再溶解,而非过饱和。因此,体外沉淀实验中观察到的不同剂量下不同的过饱和稳定性并未反映在体内吸收上。这些发现可能有助于设计高效的过饱和制剂,并验证和改进当前的预测方法。